52158 Federal Register / Vol. 86, No. 179 / Monday, September 20, 2021 / Notices 

4. Savanna Starkey on behalf of The Estate 

of R. S., Deceased, Brandenburg, Kentucky, 

Court of Federal Claims No: 21–1646V 

5. Joseph Delory, West Des Moines, Iowa, 

Court of Federal Claims No: 21–1648V 

6. David Vazquez-Gonzalez, San Juan, Puerto 

Rico, Court of Federal Claims No: 21– 

1649V 

7. Emyli Ferguson and Jeremy Ferguson on 

behalf of J. F., Glendale, Arizona, Court of 

Federal Claims No: 21–1650V 

8. Jeffrey Sears and Brittney Sears on behalf 

of G. S., Roseville, New York, Court of 

Federal Claims No: 21–1651V 

9. Jennifer L. Portock, Virginia Beach, 

Virginia, Court of Federal Claims No: 21– 

1653V 

10. Weldon Wilson, Scottsdale, Arizona, 

Court of Federal Claims No: 21–1655V 

11. Barbie Willett, Tyler, Texas, Court of 

Federal Claims No: 21–1656V 

12. Deborah Beckwith, Louisville, Kentucky, 

Court of Federal Claims No: 21–1660V 

13. Anthony Flores, Lovington, New Mexico, 

Court of Federal Claims No: 21–1661V 

14. Louis Post, Poughkeepsie, New York, 

Court of Federal Claims No: 21–1662V 

15. Chris Van Hulse, Jr., Phoenix, Arizona, 

Court of Federal Claims No: 21–1663V 

16. Michelle Azzopardi, Dearborn, Michigan, 

Court of Federal Claims No: 21–1668V 

17. Deborah Loring, Keene, New Hampshire, 

Court of Federal Claims No: 21–1670V 

18. John Mohnal, Philadelphia, 

Pennsylvania, Court of Federal Claims No: 

21–1671V 

19. Steven Brooks, Oshkosh, Wisconsin, 

Court of Federal Claims No: 21–1672V 

20. Sheila Cullen, Washington, District of 

Columbia, Court of Federal Claims No: 21– 

1673V 

21. Melanie Worsley, Topeka, Kansas, Court 

of Federal Claims No: 21–1674V 

22. Elizabeth Sears, Lawrenceville, New 

Jersey, Court of Federal Claims No: 21– 

1677V 

23. Amy Gray, Boise, Idaho, Court of Federal 

Claims No: 21–1678V 

24. Darlene E. Milne, Bellevue, Washington, 

Court of Federal Claims No: 21–1679V 

25. Krista Elvin O’Brien and Robert O’Brien 

on behalf of M. O., Phoenix, Arizona, Court 

of Federal Claims No: 21–1680V 

26. Alyssa Huber, Columbia, Tennessee, 

Court of Federal Claims No: 21–1681V 

27. Ileana Matta on behalf of I. R., Boston, 

Massachusetts, Court of Federal Claims No: 

21–1682V 

28. Cori Rivas, Peoria, Illinois, Court of 

Federal Claims No: 21–1683V 

29. Chelsea Pomponio, Lancaster, 

Pennsylvania, Court of Federal Claims No: 

21–1687V 

30. Keith Tillman, Salt Lake City, Utah, Court 

of Federal Claims No: 21–1688V 

31. Kyle Pappas, Indianapolis, Indiana, Court 

of Federal Claims No: 21–1690V 

32. Gregory Petraco, Port Jefferson Station, 

New York, Court of Federal Claims No: 21– 

1691V 

33. Karrolee Tomchak, Santa Monica, 

California, Court of Federal Claims No: 21– 

1696V 

34. Robert M. Claypool, Lancaster, Ohio, 

Court of Federal Claims No: 21–1697V 

35. E. R. Hightower-Newell on behalf of R. B. 

Newell, North Las Vegas, Nevada, Court of 

Federal Claims No: 21–1698V 

36. Ryan Sughrue, West Windsor, New 

Jersey, Court of Federal Claims No: 21– 

1699V 

37. Arturo Vasquez, II, Phoenix, Arizona, 

Court of Federal Claims No: 21–1700V 

38. Michelle Johnson, Springdale, Ohio, 

Court of Federal Claims No: 21–1707V 

39. Rhonda Bryan, Tomball, Texas, Court of 

Federal Claims No: 21–1708V 

40. Pamela Lewis-Nunez, Redondo Beach, 

California, Court of Federal Claims No: 21– 

1709V 

41. Nancy Olivo, Glendale, New York, Court 

of Federal Claims No: 21–1710V 

42. Christopher Hudson, Rockledge, Florida, 

Court of Federal Claims No: 21–1711V 

43. Melissa B. Shine, Morehead City, North 

Carolina, Court of Federal Claims No: 21– 

1717V 

44. Richard J. Tumas, Charlotte, North 

Carolina, Court of Federal Claims No: 21– 

1718V 

45. Yvette Moyler, Columbus, Ohio, Court of 

Federal Claims No: 21–1720V 

46. Michael Ritchey and Monica Ritchey on 

behalf of G. R., Little Rock, Arkansas, Court 

of Federal Claims No: 21–1724V 

47. Nadine Robbins, Hyde Park, New York, 

Court of Federal Claims No: 21–1726V 

48. Rivka Iliovits and Mordechie Iliovits on 

behalf of L. I., Staten Island, New York, 

Court of Federal Claims No: 21–1727V 

49. Stephanie Felix and Ashton Felix on 

behalf of E. A. F., Bonita, California, Court 

of Federal Claims No: 21–1728V 

50. Jill Shanti Zinzi, Phoenix, Arizona, Court 

of Federal Claims No: 21–1729V 

51. Rebekah Schaffer, Cheyenne, Wyoming, 

Court of Federal Claims No: 21–1731V 

52. Lori Wilson on behalf of A. W., Phoenix, 

Arizona, Court of Federal Claims No: 21– 

1732V 

53. Katherine Miller, Huntingtown, 

Maryland, Court of Federal Claims No: 21– 

1733V 

54. Paige Graves on behalf of D. G., 

Bartonville, Texas, Court of Federal Claims 

No: 21–1734V 

55. Paloma Flood, Oviedo, Florida, Court of 

Federal Claims No: 21–1738V 

56. David D. Bronson, Rancho Santa 

Margarita, California, Court of Federal 

Claims No: 21–1741V 

57. Robert Zampitella, Philadelphia, 

Pennsylvania, Court of Federal Claims No: 

21–1743V 

58. Aina Rizvi, Phoenix, Arizona, Court of 

Federal Claims No: 21–1744V 

59. Claire Panella, Stuart, Florida, Court of 

Federal Claims No: 21–1748V 

60. Deborah Hammond, East Norriton, 

Pennsylvania, Court of Federal Claims No: 

21–1749V 

61. Monique Coombes, Boise, Idaho, Court of 

Federal Claims No: 21–1750V 

62. Dr. Michelle Perez, Stratford, 

Connecticut, Court of Federal Claims No: 

21–1753V 

63. Matthew Rivera, Pembroke Pines, Florida, 

Court of Federal Claims No: 21–1754V 

64. Wendy Miller, Torrington, Connecticut, 

Court of Federal Claims No: 21–1756V 

65. Nancy Sorge, Monroe, Connecticut, Court 

of Federal Claims No: 21–1759V 

66. Monica Godoy, Seattle, Washington, 

Court of Federal Claims No: 21–1760V 

67. Christy Bright, Houston, Texas, Court of 

Federal Claims No: 21–1761V 

68. Barton Bond, Fayetteville, Georgia, Court 

of Federal Claims No: 21–1764V 

69. Mary Jo Drcar, Mentor, Ohio, Court of 

Federal Claims No: 21–1766V 

70. Justin Boggs, Wellesley Hills, 

Massachusetts, Court of Federal Claims No: 

21–1767V 

71. Robert Schenck, Spring Hill, Florida, 

Court of Federal Claims No: 21–1768V 

72. Amarah Elzabad, Boston, Massachusetts, 

Court of Federal Claims No: 21–1771V 

73. Silvia Bavli, Phoenix, Arizona, Court of 

Federal Claims No: 21–1772V 

74. Felicia R. Williams, St. Louis, Missouri, 

Court of Federal Claims No: 21–1774V 

75. Fazal Siddiqui, Chicago, Illinois, Court of 

Federal Claims No: 21–1776V 

76. Tommy E. Martin, Mt. Holly, North 

Carolina, Court of Federal Claims No: 21– 

1777V 

77. Lynn Peterson, Waukesha, Wisconsin, 

Court of Federal Claims No: 21–1778V 

78. Bailey Thomas on behalf of A. B., 

Englewood, New Jersey, Court of Federal 

Claims No: 21–1780V 

79. Anita Richardson, Pensacola, Florida, 

Court of Federal Claims No: 21–1781V 

80. Leah Gonzalez-Guzman, White Plains, 

New York, Court of Federal Claims No: 21– 

1782V 

[FR Doc. 2021–20233 Filed 9–17–21; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Findings of research 

misconduct have been made against Ya 

Wang, M.D., Ph.D. (Respondent), retired 

Professor and Director, Division of 

Experimental Radiation Oncology, 

Department of Radiation Oncology, 

Winship Cancer Institute, Emory 

University (EU). Respondent engaged in 

research misconduct in research 

supported by U.S. Public Health Service 

(PHS) funds, specifically National 

Cancer Institute (NCI), National 

Institutes of Health (NIH), grants P30 

CA138292 and R01 CA186129 and 

National Institute of General Medical 

Sciences (NIGMS), NIH, grant R01 

GM080771. The administrative actions, 

including debarment for a period of four 

(4) years, were implemented beginning 

on August 4, 2021, and are detailed 

below. 

FOR FURTHER INFORMATION CONTACT: 

Wanda K. Jones, Dr. P.H., Acting 

Director, Office of Research Integrity, 

Federal Register / Vol. 86, No. 179 / Monday, September 20, 2021 / Notices 52159 

1101 Wootton Parkway, Suite 240, 

Rockville, MD 20852, (240) 453–8200. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Office of Research 

Integrity (ORI) has taken final action in 

the following case: 

Ya Wang, M.D., Ph.D., Emory 

University: Based on the report of an 

inquiry conducted by EU and analysis 

conducted by ORI in its oversight 

review, ORI found that Dr. Ya Wang, 

retired Professor and Director, Division 

of Experimental Radiation Oncology, 

Department of Radiation Oncology, 

Winship Cancer Institute, EU, engaged 

in research misconduct in research 

supported by PHS funds, specifically 

NCI, NIH, grants P30 CA138292 and R01 

CA186129 and NIGMS, NIH, grant R01 

GM080771. 

Respondent neither admits nor denies 

ORI’s findings of research misconduct. 

The settlement is not an admission of 

liability on the part of the Respondent. 

The parties entered into a Voluntary 

Exclusion Agreement to conclude this 

matter without further expenditure of 

time, finances, or other resources. 

ORI found that Respondent engaged 

in research misconduct by knowingly, 

intentionally, and/or recklessly 

falsifying data that were included in the 

following one (1) PHS grant application 

and six (6) published papers: 

• R21 HL154577–01, ‘‘GPRC5A 

Inhibits Error-Prone Repair to Maintain 

Lung Genomic Integrity,’’ submitted to 

the National Heart, Lung, and Blood 

Institute (NHLBI), NIH, on December 13, 

2019. 

• miR–21-Mediated Radioresistance 

Occurs via Promoting Repair of DNA 

Double Strand Breaks. J Biol Chem. 2017 

Feb 24;292(8):3531–40; doi: 10.1074/ 

jbc.M116.772392 (hereafter referred to 

as ‘‘J Biol Chem. 2017’’). Retraction in: 

J Biol Chem. 2020 May 1;295(18):6250; 

doi: 10.1074/jbc.W120.013725. 

• Distinct Roles of Ape1 Protein, an 

Enzyme Involved in DNA Repair, in 

High or Low Linear Energy Transfer 

Ionizing Radiation-Induced Cell Killing. 

J Biol Chem. 2014 Oct 31; 

289(44):30635–44; doi: 10.1074/ 

jbc.M114.604959 (hereafter referred to 

as ‘‘J Biol Chem. 2014’’). Retraction in: 

J Biol Chem. 2020 May 1;295(18):6249; 

doi: 10.1074/jbc.W120.013724. 

• OCT4 as a Target of miR–34a 

Stimulates p63 but Inhibits p53 to 

Promote Human Cell Transformation. 

Cell Death Dis. 2014 Jan 23;5(1):e1024; 

doi: 10.1038/cddis.2013.563 (hereafter 

referred to as ‘‘Cell Death Dis. 2014’’). 

• MicroRNA–21 Modulates the Levels 

of Reactive Oxygen Species by Targeting 

SOD3 and TNFa. Cancer Res. 2012 Sep 

15;72(18):4707–13; doi: 10.1158/0008– 

5472.CAN–12–0639 (hereafter referred 

to as ‘‘Cancer Res. 2012a’’). 

• RNAi-Mediated Targeting of 

Noncoding and Coding Sequences in 

DNA Repair Gene Messages Efficiently 

Radiosensitizes Human Tumor Cells. 

Cancer Res. 2012 Mar 1; 72(5):1221–8; 

doi: 10.1158/0008–5472.CAN–11–2785 

(hereafter referred to as ‘‘Cancer Res. 

2012b’’). 

• Over-Expression of miR–100 is 

Responsible for the Low-Expression of 

ATM in the Human Glioma Cell Line: 

M059J. DNA Repair (Amst). 2010 Nov 

10;9(11):1170–5; doi: 10.1016/ 

j.dnarep.2010.08.007 (hereafter referred 

to as ‘‘DNA Repair 2010’’). 

ORI found that respondent 

knowingly, intentionally, and/or 

recklessly falsified protein immunoblot 

data by reusing and relabeling the same 

images to represent different 

experimental conditions in mammalian 

tissue culture models of DNA damage 

and repair in eighteen (18) figure panels 

in eleven (11) figures in one (1) grant 

application and six (6) published 

papers. 

Specifically: 

• Western blot images for total 

protein expression in distinct transgenic 

mouse cell lines were falsified by 

reusing immunoblot bands and 

relabeling them to represent different 

experiments in eleven (11) figure panels 

in two (2) papers, including: 

—Figure 3D in J Biol Chem. 2017, 

representing b-actin expression (left 

side panel) in wildtype (WT), 

microRNA–21 (miR–21) knock-in, and 

miR–21¥/¥ mouse embryonic 

fibroblast (MEF) cells exposed to 

irradiation 

—Figure 4C in J Biol Chem. 2017, 

representing DNA–PKcs expression in 

miR–21 knock-in MEF cells exposed 

to irradiation 

—Figure 5A in J Biol Chem. 2017, 

representing CDC25A and b-actin 

expression in WT, GSK3B¥/¥, and 

Cyclin D1¥/¥ MEF cells transfected 

with control or gene-specific silencing 

RNA (siRNA) 

—Figure 1 in J Biol Chem. 2014, 

representing b-actin expression in 

Ku80¥/¥ (Figure 1A) and Ogg1¥/¥

(Figure 1C) MEF cells transfected with 

expression or control vectors 

—Figure 3 in J Biol Chem. 2014, 

representing H2A expression in WT 

MEF (Figure 3A), Ku80¥/¥ MEF 

(Figure 3B), Ogg1¥/¥ MEF (Figure 

3C), and Ogg1+ (rescue) MEF (Figure 

3D) cells transfected with expression 

or control vectors and in the absence 

or presence of radiation exposure 

—Figure 3D in J Biol Chem. 2014, 

representing Mre11 (left panel) 

expression in Ogg1+ (rescue) MEF 

cells transfected with expression or 

control vectors in the absence or 

presence of radiation exposure 

—Figure 4B in J Biol Chem. 2014, 

representing Mre11 expression in 

Ogg1¥/¥ MEF cells with control or 

Ape1 expression vector in the 

presence of low or high linear energy 

transfer (LET) irradiation 

—Figure 5C in J Biol Chem. 2014, 

representing Ape1 and b-actin 

expression in WT MEF cells with or 

without gene depletion and 

transfected with control or various 

Ape1 expression vectors 

• western blot images for total protein 

expression in human cell lines subject 

to gene depletion and/or overexpression 

were falsified by reusing immunoblot 

bands and relabeling them to represent 

different experiments in seven (7) figure 

panels in five (5) papers and one (1) 

grant application, including: 

—Figure 4A in NIH grant application 

R21 HL154577–01, representing 

GPRC5A levels in different patientderived cell lines with gene 

suppression or depletion 

—Figure 4D in J Biol Chem. 2017, 

representing total DNA–PKcs, 

phosphorylated DNA–PKcs, CDC25A, 

and GSK3B levels in human 

embryonic kidney cells transfected 

with controls or various expression 

vectors and/or miR–21 mimics 

—Figure 5C in J Biol Chem. 2017, 

representing CDC25A, GSK3B, Cyclin 

D1, and b-actin expression in human 

embryonic kidney cells with or 

without gene depletion and 

transfected with controls or miR–21 

mimics 

—Figure 5B in Cell Death Dis. 2014, 

representing p53 and p63 levels in 

human lung epithelial cells with or 

without gene depletion 

—Figure 3A in Cancer Res. 2012a, 

representing TNFa levels in control 

and miR–21 overexpressing human 

lung epithelial cells at different time 

points following irradiation 

—Figure 5A in Cancer Res. 2012b, 

representing XRCC4 levels in both 

human lung and brain epithelial cells 

with gene depletion at multiple time 

points and treated with or without an 

artificial microRNA 

—Figure 3A in DNA Repair 2010, 

representing ATM and Ku70 levels in 

human glioblastoma-derived cells 

with or without gene depletion 

• western blot images for proteins 

from chromatin DNA complexes in 

mouse cell lines transfected with 

control or expression vectors and in the 

absence or presence of irradiation were 

falsified by reusing immunoblot bands 

52160 Federal Register / Vol. 86, No. 179 / Monday, September 20, 2021 / Notices 

and relabeling them to represent 

different experiments in three (3) figure 

panels in one (1) paper, including: 

—Figure 3 in J Biol Chem. 2014, 

representing chromatin-bound gH2AX levels in WT MEF (Figure 3A), 

Ogg1¥/¥ MEF (Figure 3C), and Ogg1+

(rescue) MEF (Figure 3D) cells 

transfected with a control or 

expression vector and in the absence 

or presence of irradiation 

Dr. Wang entered into a Voluntary 

Exclusion Agreement (Agreement) and 

voluntarily agreed to the following: 

(1) Respondent agreed to exclude 

herself voluntarily for a period of four 

(4) years beginning on August 4, 2021, 

from any contracting or subcontracting 

with any agency of the United States 

Government and from eligibility for or 

involvement in nonprocurement 

programs of the United States 

Government referred to as ‘‘covered 

transactions’’ pursuant to HHS’ 

Implementation (2 CFR part 376) of 

OMB Guidelines to Agencies on 

Governmentwide Debarment and 

Suspension, 2 CFR part 180 (collectively 

the ‘‘Debarment Regulations’’). 

(2) Respondent agreed to exclude 

herself voluntarily from serving in any 

advisory capacity to PHS including, but 

not limited to, service on any PHS 

advisory committee, board, and/or peer 

review committee, or as a consultant for 

a period of four (4) years, beginning on 

August 4, 2021. 

(3) As a condition of the Agreement, 

Respondent will request that the 

following papers be corrected or 

retracted in accordance with 42 CFR 

93.407(a)(1) and § 93.411(b): 

• Cell Death Dis. 2014 Jan;5(1):e1024 

• Cancer Res. 2012 Sep 15;72(18):4707– 

13 

• Cancer Res. 2012 Mar 1;72(5):1221–8 

• DNA Repair (Amst). 2010 Nov 

10;9(11):1170–5 

Respondent will copy ORI and the 

Research Integrity Officer at EU on the 

correspondence. 

Dated: September 15, 2021. 

Wanda K. Jones, 

Acting Director, Office of Research Integrity, 

Office of the Assistant Secretary for Health. 

[FR Doc. 2021–20268 Filed 9–17–21; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

[Document Identifier: OS–0990–xxxx] 

Agency Father Generic Information 

Collection Request. 60-Day Public 

Comment Request 

AGENCY: Office of the Secretary, Health 

and Human Services (HHS). 

ACTION: 60-Day notice of public 

information collections. 

SUMMARY: In compliance with the 

requirement of the Paperwork 

Reduction Act of 1995, the Office of the 

Secretary (OS), Department of Health 

and Human Services, is publishing the 

following summary of a proposed 

collection for public comment. 

DATES: Comments on the ICR must be 

received on or before November 19, 

2021. 

ADDRESSES: Submit your comments to 

Sherrette.Funn@hhs.gov or by calling 

(202) 795–7714. 

FOR FURTHER INFORMATION CONTACT: 

When submitting comments or 

requesting information, please include 

the document identifier 0990-New-60D, 

and project title for reference, to 

Sherrette Funn, the Reports Clearance 

Officer, Sherrette.funn@hhs.gov, or call 

202–795–7714. 

SUPPLEMENTARY INFORMATION: Interested 

persons are invited to send comments 

regarding this burden estimate or any 

other aspect of this collection of 

information, including any of the 

following subjects: (1) The necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions; (2) the accuracy 

of the estimated burden; (3) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(4) the use of automated collection 

techniques or other forms of information 

technology to minimize the information 

collection burden. 

Title of the Collection: Evaluation of 

the National Hypertension Control 

Initiative (NHCI). 

Type of Collection: NEW Generic. 

OMB No. 0990—OS/Office of Minority 

Health (OMH) 

Abstract: As part of the federal 

response to COVID–19, the U.S. 

Department of Health and Human 

Services (HHS) has funded a new 

initiative involving two cooperative 

agreements with the American Heart 

Association (AHA) to improve COVID– 

19-related health outcomes by 

addressing hypertension (high blood 

pressure) among racial and ethnic 

minority populations. 

The $32 million project from the HHS 

Office of Minority Health (OMH) and 

the Health Resources and Services 

Administration (HRSA) Bureau of 

Primary Health Care will support the 

implementation of the National 

Hypertension Control Initiative (NHCI), 

a national initiative to improve blood 

pressure control among the most at-risk 

populations, including racial and ethnic 

minorities. 

The NHCI will support 350 

participating HRSA-funded health 

centers by providing patient and 

provider education and training for 

effective hypertension control as well as 

integration of remote blood pressure 

monitoring technology into the 

treatment of hypertension for patients 

served by participating health centers. 

The project will also utilize the 

American Heart Association’s targeted 

media campaigns and existing 

partnerships with community-based 

organizations (CBOs) to help reach 

Black, Latino, and other impacted 

communities with (i) culturally and 

linguistically appropriate messages, (ii) 

access to blood pressure screenings, and 

(iii) connection to health centers to 

encourage proper treatment and 

management of hypertension of 

screened individuals. This initiative 

serves to increase the number of adult 

patients with controlled hypertension 

and reduce the potential risk of COVIDrelated health outcomes. 

AHA aims to conduct an evaluation to 

assess the feasibility of the 

implementation of each of the three 

NHCI strategies. The findings of this 

evaluation will inform the improvement 

and tailoring of AHA’s communication 

approaches about the importance of and 

techniques for improving blood pressure 

control, including the benefits of 

accurately measuring, rapidly acting, 

and having a patient-focused approach 

to blood pressure control. 

Methodology: The evaluation of the 

NHCI project will use a mixed methods 

design, integrating both quantitative and 

qualitative data collection and analyses. 

Three main goals of data collection will 

be to: (1) Track and monitor systems 

change implementation process 

information from Community Health 

Centers (CHCs) on a quarterly basis, (2) 

assess the capacity of NHCI partners to 

implement the NHCI project, their 

needs, the strengths and weaknesses of 

the systems change approach, and the 

feasibility of the implementation of the 

NHCI in their organizations and 

communities, and (3) assess the reach 

and success of NHCI project strategies 

implemented by partners.